search
Back to results

Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold

Primary Purpose

Common Cold, Pharyngitis, Tonsillitis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Acetylsalicylic Acid (Aspirin, BAYE4465)
Lidocain
Placebo
Sponsored by
Bayer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Common Cold focused on measuring Sore Throat

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females of at least 18 years of age
  • Onset of common cold within the last 3 days (12 to 72 hours)
  • History of at least 4 symptoms associated with URTI in the last 24 hours out of runny nose, stuffy nose, sneezing, wet cough, dry cough, sweating, earache, ear fullness, sinus pressure/pain, head heaviness, muscle aches and pains, feverish discomfort, chills, hoarseness, sore throat, scratchy throat and headache as documented in the history of URTI
  • Current sore throat confirmed by a score ≥ 6 on a 11-category vertical ordinal scale for sore throat pain
  • Findings that confirmed the presence of tonsillopharyngitis

Exclusion Criteria:

  • Pregnancy (i.e. positive pregnancy test at baseline)
  • Breastfeeding
  • History of hypersensitivity (allergic reaction) to ASA or any other NSAID
  • History of hypersensitivity (allergic reaction) to lidocaine
  • History or acute state of peptic ulceration or gastrointestinal bleeding
  • History of bleeding tendency
  • History of asthma
  • Clinical diagnosis of chickenpox or influenza
  • History or presence of severe liver or kidney disease
  • Intake of short-acting analgesics (e.g. ASA, paracetamol, ibuprofen, diclofenac) either as a single ingredient or as part of a combination cold product in the last 6 hours, or intake of long-acting analgesics (e.g. naproxen) in the last 12 hours, or intake of any other NSAID in the last 24 hours
  • Use of any local or systemic short-acting cough and cold preparation (e.g. decongestant or antihistaminic drug) in the last 12 hours
  • Use of any cough or sore throat lozenges/candies or any menthol-containing product (including mentholated tissues) in the last 6 hours
  • Current intake or requirement of any prescription medication for the current treatment of acute respiratory tract illness
  • Administration of anticoagulants in the last 7 days
  • Inability to breathe through the nose or a history of chronic mouth breathing
  • Presence of any severe concomitant disease or condition which, in the opinion of the investigator, is a reason for exclusion, e.g. serious cardiovascular diseases (in particular arrhythmias), treatment with antiarrhythmics or methotrexate

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Arm 1

Arm 2

Arm 3

Arm 4

Arm Description

Outcomes

Primary Outcome Measures

Sum of pain intensity differences SPID
Pain intensity difference to baseline (PID12 min)
Pain intensity difference to baseline (PID120 min)

Secondary Outcome Measures

Pain intensity difference to baseline (PID)
Total pain relief to baseline (TOTPAR)
Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain)
Overall assessment of treatment
Assessment of safety and tolerability

Full Information

First Posted
May 25, 2011
Last Updated
October 16, 2023
Sponsor
Bayer
search

1. Study Identification

Unique Protocol Identification Number
NCT01361399
Brief Title
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
Official Title
A 4-arm, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Single Dose, Parallel Group Study Comparing Efficacy and Safety of a Fixed Combination of 500 mg Acetylsalicylic Acid + 4 mg Lidocaine With 500 mg Acetylsalicylic Acid and 4 mg Lidocaine Monotherapy as Well as Placebo in Adult Patients With Sore Throat Associated With a Common Cold.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
November 30, 2004 (Actual)
Primary Completion Date
May 28, 2005 (Actual)
Study Completion Date
May 28, 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the analgesic efficacy of a single dose of a fixed combination of 500 mg Aspirin (Acetylsalicylic Acid) and 4 mg Lidocaine in adult patients with sore throat associated with a common cold in comparison to a single treatment with 500 mg Aspirin or 4 mg Lidocaine alone as well a Placebo (treatment without any active ingredient). The combination of Aspirin and Lidocaine in a single lozenge is expected to provide relief from sore throat pain by sequential action. A very fast inset of action will be achieved by the locally acting Lidocaine and a long duration of action will be achieved by the systemically acting Aspirin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Common Cold, Pharyngitis, Tonsillitis
Keywords
Sore Throat

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1088 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Experimental
Arm Title
Arm 2
Arm Type
Active Comparator
Arm Title
Arm 3
Arm Type
Active Comparator
Arm Title
Arm 4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Intervention Description
Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
Intervention Type
Drug
Intervention Name(s)
Acetylsalicylic Acid (Aspirin, BAYE4465)
Intervention Description
Single oral application of Aspirin (as lozenge)
Intervention Type
Drug
Intervention Name(s)
Lidocain
Intervention Description
Single oral application of Lidocain (as lozenge)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Single oral application of Placebo (as lozenge)
Primary Outcome Measure Information:
Title
Sum of pain intensity differences SPID
Time Frame
120 minutes
Title
Pain intensity difference to baseline (PID12 min)
Time Frame
12 minutes
Title
Pain intensity difference to baseline (PID120 min)
Time Frame
120 minutes
Secondary Outcome Measure Information:
Title
Pain intensity difference to baseline (PID)
Time Frame
3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose
Title
Total pain relief to baseline (TOTPAR)
Time Frame
3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose
Title
Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain)
Time Frame
60, 120, 180, and 240 minutes post dose
Title
Overall assessment of treatment
Time Frame
240 minutes
Title
Assessment of safety and tolerability
Time Frame
240 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females of at least 18 years of age Onset of common cold within the last 3 days (12 to 72 hours) History of at least 4 symptoms associated with URTI in the last 24 hours out of runny nose, stuffy nose, sneezing, wet cough, dry cough, sweating, earache, ear fullness, sinus pressure/pain, head heaviness, muscle aches and pains, feverish discomfort, chills, hoarseness, sore throat, scratchy throat and headache as documented in the history of URTI Current sore throat confirmed by a score ≥ 6 on a 11-category vertical ordinal scale for sore throat pain Findings that confirmed the presence of tonsillopharyngitis Exclusion Criteria: Pregnancy (i.e. positive pregnancy test at baseline) Breastfeeding History of hypersensitivity (allergic reaction) to ASA or any other NSAID History of hypersensitivity (allergic reaction) to lidocaine History or acute state of peptic ulceration or gastrointestinal bleeding History of bleeding tendency History of asthma Clinical diagnosis of chickenpox or influenza History or presence of severe liver or kidney disease Intake of short-acting analgesics (e.g. ASA, paracetamol, ibuprofen, diclofenac) either as a single ingredient or as part of a combination cold product in the last 6 hours, or intake of long-acting analgesics (e.g. naproxen) in the last 12 hours, or intake of any other NSAID in the last 24 hours Use of any local or systemic short-acting cough and cold preparation (e.g. decongestant or antihistaminic drug) in the last 12 hours Use of any cough or sore throat lozenges/candies or any menthol-containing product (including mentholated tissues) in the last 6 hours Current intake or requirement of any prescription medication for the current treatment of acute respiratory tract illness Administration of anticoagulants in the last 7 days Inability to breathe through the nose or a history of chronic mouth breathing Presence of any severe concomitant disease or condition which, in the opinion of the investigator, is a reason for exclusion, e.g. serious cardiovascular diseases (in particular arrhythmias), treatment with antiarrhythmics or methotrexate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Facility Information:
City
Mocow
ZIP/Postal Code
117574
Country
Russian Federation
City
Moscow
ZIP/Postal Code
105064
Country
Russian Federation
City
Moscow
ZIP/Postal Code
114765
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117321
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117342
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117393
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117418
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117421
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117485
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117513
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117588
Country
Russian Federation
City
Moscow
ZIP/Postal Code
127299
Country
Russian Federation
City
Novosibirsk
ZIP/Postal Code
630099
Country
Russian Federation
City
Kiev
ZIP/Postal Code
02091
Country
Ukraine
City
Kiev
ZIP/Postal Code
02222
Country
Ukraine
City
Kiev
ZIP/Postal Code
02232
Country
Ukraine
City
Kiev
ZIP/Postal Code
03049
Country
Ukraine
City
Lugansk
ZIP/Postal Code
91011
Country
Ukraine
City
Lugansk
ZIP/Postal Code
91055
Country
Ukraine

12. IPD Sharing Statement

Learn more about this trial

Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold

We'll reach out to this number within 24 hrs